Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven G Potkin

Showing results (11-20 of 217) with videos related to

Pageof 22
Sort By:
Therapeutic Advances in Psychopharmacology|February 3, 2016
A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophreniaSteven G Potkin, Tatsuya Kimura, John Guarino
The International Journal of Neuropsychopharmacology|August 9, 2005
Targeting acetylcholinesterase and butyrylcholinesterase in dementiaRoger M Lane, Steven G Potkin, Albert Enz
Clinical Schizophrenia & Related Psychoses|May 22, 2014
A Pilot Study of Cultural/Racial Differences in Patient Perspectives on Long-Acting Injectable Antipsychotics for the Treatment of SchizophreniaSteven G Potkin, Rimal Bera, Anna Eramo, et al.
Schizophrenia Research|November 5, 2002
Neurocognitive performance does not correlate with suicidality in schizophrenic and schizoaffective patients at risk for suicideSteven G Potkin, Ravi Anand, Larry Alphs, et al.
Journal of Clinical Psychopharmacology|January 2, 2013
A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidoneSteven G Potkin, Sheldon Preskorn, Marla Hochfeld, et al.
Schizophrenia Research|September 6, 2011
Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorderSteven G Potkin, Masaaki Ogasa, Josephine Cucchiaro, et al.
Biological Psychiatry|August 24, 2014
Imaging genetics approaches to identify mechanisms in severe mental illnessSteven G Potkin, Fabio Macciardi, Theo G M van Erp
Human Molecular Genetics|September 28, 2002
Pharmacogenomics in schizophrenia: the quest for individualized therapyVincenzo S Basile, Mario Masellis, Steven G Potkin, et al.
Biological Psychiatry|January 7, 2003
MRNA expression patterns and distribution of white matter neurons in dorsolateral prefrontal cortex of depressed patients differ from those in schizophrenia patientsMargherita Molnar, Steven G Potkin, William E Bunney, et al.
The Journal of Clinical Psychiatry|November 11, 2010
Using new antipsychotics in your clinical practiceSteven G Potkin, Adrian Preda, Amir H Kalali, et al.
Pageof 22

Showing results (11-20 of 217) with videos related to

Sort By:
Pageof 22
Therapeutic Advances in Psychopharmacology|February 3, 2016
A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophreniaSteven G Potkin, Tatsuya Kimura, John Guarino
The International Journal of Neuropsychopharmacology|August 9, 2005
Targeting acetylcholinesterase and butyrylcholinesterase in dementiaRoger M Lane, Steven G Potkin, Albert Enz
Clinical Schizophrenia & Related Psychoses|May 22, 2014
A Pilot Study of Cultural/Racial Differences in Patient Perspectives on Long-Acting Injectable Antipsychotics for the Treatment of SchizophreniaSteven G Potkin, Rimal Bera, Anna Eramo, et al.
Schizophrenia Research|November 5, 2002
Neurocognitive performance does not correlate with suicidality in schizophrenic and schizoaffective patients at risk for suicideSteven G Potkin, Ravi Anand, Larry Alphs, et al.
Journal of Clinical Psychopharmacology|January 2, 2013
A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidoneSteven G Potkin, Sheldon Preskorn, Marla Hochfeld, et al.
Schizophrenia Research|September 6, 2011
Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorderSteven G Potkin, Masaaki Ogasa, Josephine Cucchiaro, et al.
Biological Psychiatry|August 24, 2014
Imaging genetics approaches to identify mechanisms in severe mental illnessSteven G Potkin, Fabio Macciardi, Theo G M van Erp
Human Molecular Genetics|September 28, 2002
Pharmacogenomics in schizophrenia: the quest for individualized therapyVincenzo S Basile, Mario Masellis, Steven G Potkin, et al.
Biological Psychiatry|January 7, 2003
MRNA expression patterns and distribution of white matter neurons in dorsolateral prefrontal cortex of depressed patients differ from those in schizophrenia patientsMargherita Molnar, Steven G Potkin, William E Bunney, et al.
The Journal of Clinical Psychiatry|November 11, 2010
Using new antipsychotics in your clinical practiceSteven G Potkin, Adrian Preda, Amir H Kalali, et al.
Pageof 22